<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	[data-slide='12'] > h2 { margin-bottom:12px; }
	.cols { height:384px; margin-top:45px; }
	.cols > li, .diagnosis > li, .brcam > li { font-size:16px; line-height:18px; }
	.cols > li { float:left; width:174px; height:inherit; text-align:center; font-family:interstatebold-condensed; border-right:1px dashed #004d74; }
	.cols > li:nth-child(2) { width:372px; }
	.cols > li:last-child { width:395px; }
	.cols > li span { display:block; color:#b2d234; font-size:20px; line-height:24px; margin-top:-30px; }
	div[class^=diagnosis] { height:80px; text-align:left; padding-left:45px; border-top:2px solid #bbbdbf; position:relative; opacity:0.25; }
	div[class^=diagnosis-1] { margin-top:32px; }
	div[class^=diagnosis-2], div[class^=diagnosis-1].active { border-bottom: 2px solid #bbbdbf; }
	div[class^=diagnosis-1].active + div[class^=diagnosis-2] { border-top:none; }
	div[class^=diagnosis-].active { opacity:1; }
	div[class^=diagnosis-]:before, div[class^=diagnosis-]:after { position:absolute; top:0; bottom:0; margin:auto 0; }
	div[class^=diagnosis-]:after { content:""; left:5px; width:32px; height:80px; background: url(img/woman.png) 0 center no-repeat; background-size:100% auto; }
	div[class^=diagnosis-]:before { content:"\e603"; color:#bbbdbf; font-size:32px; height:30px; right:0; transform:rotate(-90deg); }
	.cols div i, .diagnosis i, .brcam i { display:table-cell; vertical-align:middle; height:inherit; }
	.wrap, .diagnosis > li:nth-child(n+5), .diagnosis:before, .brcam:before, .brcam span { position:absolute; }
	.diagnosis { width:100%; position:relative; }
	.wrap { width:770px; top:185px; left:174px; height: 400px; }
	.diagnosis, .diagnosis:before, .brcam, .brcam:before { height:inherit; }
	.diagnosis:before, .brcam:before { content:""; left:0; background-repeat:no-repeat; background-size:100% auto; z-index:-1; }
	.diagnosis:before { width:614px; top:68px; background-image:url(img/chart.svg); }
	.diagnosis > li, .brcam > li { float:left; background-color:#004d74; color:#ffffff; font-family:interstateregular-condensed; text-align:center; }
	.diagnosis > li { width:131px; height:112px; padding:5px 10px; background-color:#004d74; color:#ffffff; font-family:interstateregular-condensed; text-align:center; }
	.diagnosis > li:first-child { width:50px; height:36px; margin:112px 7px 0; }
	.diagnosis > li:nth-child(2), 
	.diagnosis > li:nth-child(3),
	.diagnosis > li:nth-child(4) { margin-top:75px; }
	.diagnosis > li:nth-child(n+5) { margin-right:0; right:7px; top:2px; height:108px; }
	.diagnosis > li:nth-child(5) { background-color:#b2d234; height: 125px }
	.diagnosis > li:nth-child(6) { top:143px; }
	.diagnosis > li:last-child, .diagnosis > li:nth-child(7) { top:267px;  }
	.diagnosis > li:last-child { right:183px;  }
	.diagnosis > li:last-child:after { content:""; width:10px; height:20px; position:absolute; left:-66px; background-color:#fff; bottom: -2px;  }
	.diagnosis i { width:inherit; }
	.brcam { margin-left: 33px; }
	.brcam > li { padding:10px; width:90px; height:162px; position:relative; top: 45px; text-align:center; margin-right:12px; }
	.brcam > li:first-child{ width:120px; }
	.brcam > li:nth-child(5) { margin-right:8px; }
	.brcam > li:last-child{ margin-right:0; }
	.brcam > li:nth-child(2), .brcam > li:nth-child(4) { width:82px; }
	.brcam li > span { width:25px; height:25px; left:0; right:0; margin:0 auto; bottom:-40px; font-family:interstatelight; font-size:23px; line-height:28px; }
	.brcam i { width:inherit; }
	.brcam:before { width:782px; top:0; background-image:url(img/chart2.svg); background-position:-12px 130px; }

	
	
	.btn-capsule { background-image:url(img/HGSO_icon.png); }
	.slim { position:absolute; bottom:14px; left:55px; margin-bottom:0; }
	.slim > span { display:block; }
	.slim.tall { bottom:2px; }
	
	div[class^=diagnosis-] { -webkit-transition:all 0.5s ease-in-out; transition:all 0.5s ease-in-out; }
	
	
	
</style> 
</head>
<body>
	<section id="container">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
        	<!--subslides-->
            <div class="swiper-container">
                <ul class="swiper-wrapper">
                	<!-- slide 4-->
                    <li class="swiper-slide" data-slide="12">
                         <h2><span>BRCAm TESTING</span>
                            PATIENTS WITH HGSOC ARE ELIGIBLE FOR TREATMENT WITH
LYNPARZA IF THEY HAVE A CONFIRMED BRCA MUTATION<sup data-ref="4">4</sup>
                        </h2>
                        <p>Standard of care following completion of platinum-sensitive relapsed high grade serous ovarian cancer therapy
is commonly ‘watch and wait’ (no active therapy).<sup data-ref="6">6</sup></p>
            
                        <ul class="cols">
                        	<li class="icon"><span>Diagnosis</span>
                            	<div class="diagnosis-1"><i>Ovarian Cancer<br />
Patient<br />
Journey</i></div>
                            	<div class="diagnosis-2 active"><i>Ovarian Cancer<br />
BRCA Mutation<br />
Testing Program</i></div>
                            </li>
                        	<li><span>First relapse</span></li>
                        	<li><span>Second and subsequent relapse</span></li>
                        </ul>
                        <div class="wrap">
                        	<ul class="diagnosis hide">
                        		<li><i>Test for
BRCAm</i></li>
                        		<li><i>Initial treatment:<br />
surgery +/-<br />
platinum-based<br />
chemotherapy</i></li>
                        		<li><i>Surveillance<br />
(watch & wait)</i></li>
                        		<li><i>Platinum-sensitive<br />
relapsed patients†:<br />
platinum-based<br />
chemotherapy</i></li>
                        		<li><i>BRCAm<br />
platinum-sensitive<br />
relapsed patients<br />
are eligible<br />
for maintenance<br />
treatment with<br />
Lynparza*</i></li>
                        		<li><i>Wild type BRCA<br />
patients: surveilance<br />
(watch & wait)</i></li>
                        		<li><i>Surveillance<br />
(watch & wait)</i></li>
                        		<li><i>Platinum-refractory<br />
patients:<br />
chemotherapy</i></li>
                        	</ul>
                            <ul class="brcam">
                            	<li>
                                	<i>BRCAm<br />
platinum-sensetive<br />
relapsed high grade<br />
serous ovarian<br />
cancer relapsed<br />
patients are eligible<br />
for maintenance<br />
treatment with<br />
Lynparza</i>
                               	</li>
                            	<li data-info="12a">
                                	<i>Eligibility</i>
                                	<span class="btn btn-info">i</span>
                                </li>
                            	<li data-info="12b">
                                	<i>Pre-test<br />
genetic<br />
counselling<br />
hotline<br />
1800 770 735</i>
                                	<span class="btn btn-info">i</span>
                                </li>
                            	<li data-info="12c">
                                	<i>BRCA<br />
mutation<br />
analysis &<br />
results</i>
                                	<span class="btn btn-info">i</span>
                                </li>
                            	<li data-info="12d">
                                	<i>Post-test<br />
counselling<br />
for women<br />
with a<br />
BRCA1/2<br />
mutation</i>
                                	<span class="btn btn-info">i</span>
                                </li>
                            	<li data-info="12e">
                                	<i>PARPi<br />
eligibility for<br />
women with<br />
a BRCA 1/2<br />
mutation</i>
                                	<span class="btn btn-info">i</span>
                                </li>
                            </ul>
                        </div>
                        
                        
                        <div class="footnote slim tall">
                        	HGSOC=High Grade Serous Ovarian Cancer
                            <span>* Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive<br />
relapsed BRCA-mutated (germline and/or somantic) high grade serous epithelial ovarian, fallopian tube, or primary<br />
peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy<sup data-ref="4">.4</sup><br />
<sup>†</sup> Platinum-sensitive defined by a relapse-free period of <span class="sym">≥</span>6 months following a respose to the final dose of<br />
platinum-based chemotherapy treatment.</span>
                        </div>
                       
                    </li>
                    <!-- slide 5 -->
                    <li class="swiper-slide" data-slide="5">
                         <h2><span>CLINICAL DATA – STUDY OVERVIEW</span>
                           STUDY 19 WAS A RANDOMISED, DOUBLE-BLIND,<br />
PLACEBO-CONTROLLED PHASE II CLINICAL TRIAL<sup data-ref="2">2</sup>
                        </h2>
                        <p>In Study 19, Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study
population.<sup data-ref="2">2</sup></p>
                        <div class="feature">
                        	<ul class="label">
                                <li>TOTAL STUDY platinum-sensitive
relapsed high-grade serous ovarian
cancer following complete or partial
response to prior platinum-based
therapy (N=265).<sup data-ref="2">2*</sup></li>
                                <li>Lynparza<br />
400 mg po bid
<span class="rand">Randomised 1:1<sup>2</sup></span>
Placebo<br />
po bid
</li>
                        		<li>
                                	<span>PRIMARY ENDPOINT:<br />
PFS<sup data-ref="4">4</sup></span>
<span>SECONDARY ENDPOINTS:</span>
<i>•</i> Overall survival<sup data-ref="4">4</sup><br />
<i>•</i> Disease control rate<sup data-ref="4">4</sup><br />
<i>•</i> Disease-related symptoms<sup data-ref="4">4</sup><br />
<i>•</i> Safety and tolerability
                                </li>
                        	</ul>
                        </div>
                        <p>A retrospective analysis was conducted on a pre-defined subgroup<br />
of patients with BRCA mutations. This is included 51% of patients N=136.<sup data-ref="3">3</sup></p>
<p class="footnote">*Platinum-sensitive defined by a relapse-free period of <span class="sym">≥</span>6 months following a rese final dose ponse to thof platinum-based chemotherapy treatment.</p>
                    </li>
                   
                    
                </ul><!-- end swiper-wrapper -->
                <!-- Add Arrows -->
       			<span class="swiper-button icon arrow swiper-button-next"></span>
        		<span class="swiper-button icon arrow swiper-button-prev"></span>
            </div>
            
        	<span class="logo lynp"></span>
            <span class="btn btn-capsule"></span>
        </article>
    
    <!-- popup -->
    <div class="overlay shade show">
    	<!-- reference -->
    	<div class="ref hide">
            <div class="item"> <span class="close icon"></span>
                <h1>References</h1>
                <ol></ol>
            </div>
        </div><!-- end ref -->
         <!-- info -->
        <div class="item info "><span class="arrow icon"></span>
            <!-- 12 -->
             <ul class="list hide" data-info="12a">
                <li>Diagnosis of high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer</li>
                <li>Unknown BRCA 1/2 mutation status</li>
                <li>At first or subsequent relapse</li>
                <li>At any age</li>
                <li>Irrespective of family history</li>
            </ul>
            <div data-info="12b" class="hide">
            	<p>During the patient consultation:</p>
                <ol>
                   
                    <li>Contact the genetic counselling hotline on 1800 770 735 to arrange a pre-test, telephone based<br />
        genetic counselling appointment.</li>
                    <li>Genetic counselling service provides patient with a testing kit containing the required documentation<br />
        and collection materials.</li>
                    <li>Patient attends local pathology service for blood collection and kit is sent to testing laboratory<br />
        in supplied pre-paid self-addressed satchel.</li>
                </ol>
           </div>
           <div class="hide" data-info="12c">
           		<p>BRCA mutation testing results and interpretation are sent to the referring clinician and also sent<br />
to PMCC genetic counselling service.</p>
             <ul class="list" >
                <li>National availability</li>
				<li>4-week turnaround time</li>
            </ul> 
           </div>
           <div class="hide" data-info="12d">
           		Women tested positive for germline BRCA1/2 mutation (pathogenic, likely pathogenic or VUS) and
patients with a significant family history will be assisted in accessing face-to-face post-testing genetic
counselling. Payment for post-test genetic counselling is not included in the program.
           </div>
            <div class="" data-info="12e">
           		Identification of a BRCA mutation may inform treatment options, including eligibility for a PARP inhibitor<br />
access program supported by AstraZeneca.
           </div>
            
        </div><!-- end info -->
      
       <!-- navigation -->
        <div class="item nav hide"><span class="close icon"></span>
        	<ul class="section">
        		<li data-href="1"><span>Unmet need</span></li>
        		<li data-href="2"><span>Mechanism<br />of action</span>
                	<ul>
                		<li data-href="2"><span>PARPi</span></li>
                		<li data-href="3"><span>DNA repair</span></li>
                	</ul>
                </li>
        		<li data-href="4"><span>Clinical Data</span>
                	<ul>
                		<li data-href="4"><span>Extended PFS</span></li>
                		<li data-href="5"><span>Study overview</span></li>
                		<li data-href="6"><span>BRCAm<br />sub-analysis</span></li>
                		<li data-href="7"><span>TFST<br />Exploratory Analysis</span></li>
                		<li data-href="8"><span>TSST<br />Exploratory Analysis</span></li>
                		<li data-href="9"><span>Overall Survival</span></li>
                		<li data-href="10"><span><em>Post-Hoc</em> interim exploratory analysis of os</span></li>
                		<li data-href="11"><span>Patient Characteristics</span></li>
                	</ul>
                </li>
        		<li data-href="12"><span>BRCAm+</span>
                	<ul>
                		<li data-href="12"><span>BRCAm testing</span></li>
                		<li data-href="13"><span>About BRCAm</span></li>
                		<li data-href="14"><span>Testing<br />guidelines</span></li>
                		<li data-href="15"><span>BRCAm status</span></li>
                	</ul>
                </li>
        		<li data-href="16"><span>Patient<br />Support</span>
                	<ul>
                		<li data-href="16"><span>LYNPARZA Patient&nbsp;Access Programme</span></li>
                		<li data-href="17"><span>Patient&nbsp;Support Programme</span></li>
                		<li data-href="18"><span>Patient<br />Support Kit</span></li>
                		<li data-href="19"><span>Capsule<br />companion</span></li>
                	</ul>
                </li>
        		<li data-href="20"><span>Dosing &amp;<br />administration</span>
                	<ul>
                		<li data-href="20"><span>Safety and<br />tolerability</span></li>
                		<li data-href="21"><span>Dosing</span></li>
                	</ul>
                </li>
        		<li data-href="22"><span>Summary</span></li>
        	</ul>
            
        </div><!-- end nav -->
    </div>

    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/TimelineLite.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		 var mySwiper = new Swiper('.swiper-container', {
        	paginationClickable: true,
        	direction: 'vertical',
			nextButton: '.swiper-button-next',
        	prevButton: '.swiper-button-prev',
			onSlideChangeStart: function(e){
				//console.log(e.activeIndex);
				//e.slideTo(9);
			} 
		  });
		 //mySwiper.slideTo(9);
		/* $('.indicator .arrow').on('tap', function(){ 
				$(this).toggleClass('less').prev('p').slideToggle();
		 })*/
		
	})

</script>
</body>
</html>
